RE: RE: Major Home Run If EffectiveThere is much to like about Cangene and its future is very bright............
.........the performance in 2011 continued to reflect investment in infrastructure and pipeline development to support their growing emphasis on commercial business.
.........they have a new CEO who is growth oriented who intends to focus on the various business segments and build on those with solid economics.
...........CNJ has a solid cash position of $45.5 million (
.70 per share ) and is debt-free,
............it has a strong revenue base of about $150 million which generated cash flows of nearly $16 million in 2011 and boosted the cash position by $5 million.
.............Cangene is funding the development of a revolutionary technological development for the treatment of Alzeihmers disease. It has already been tested in the laboratory and now moves to the clin ical stage.
If confirmed, this will be a company maker for Cangene.
Summary.....................pristine balance sheet with strong cash flows that should increase as the new CEO reconfigures the various business segments so as to increase overall margins.
I see a double here over the next year, and further gains in the years ahead as it rolls out its new drugs and recopnfigures its business operations.
Should the new Alzeihmers technology be effective, then we will have several multiples of 10 baggers.